Psychedelics Investing Emyria and UWA in Partnership to Commercialise Novel Serotonin-Releasing Agents for Mental Health and Neurology
Psychedelics Investing Quarterly Activities Report: Melodiol Delivers $9.3m in Revenue During H1 FY24 – a 33% Increase the PCP
psychedelics investing $12M Proposed Cash Asset Sale to Strengthen Balance Sheet, with $2.2M of Earn Outs
Psychedelics Investing Emyria Selected by Reach Wellness to Lead MDMA -Assisted Therapy Research for First Responders
Juggernaut Announces Strategic Investment by Crescat Capital Funds for 28.95% Ownership - Dr. Quinton Hennigh Technical Advisor
